Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -2256.36x is 97% below its 5-year average of -1146.75x, near the high end of its 5-year range (-11694.00x–-14.56x).
26.41% above its 12-month average of -3066.25x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -3200.25x.
INTEREST COVERAGE RATIO
-2256.36x
INTEREST COVERAGE RATIO AVG TTM
-3066.25x
INTEREST COVERAGE RATIO AVG 3Y
-1503.59x
INTEREST COVERAGE RATIO AVG 5Y
-1146.75x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+26.41%
CURRENT VS 3Y AVG
-50.06%
CURRENT VS 5Y AVG
-96.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.38x
median of 516 covered companies
CURRENT VS SECTOR MEDIAN
-35293.88%
vs the sector median at left
Lucid Diagnostics Inc.
Market Cap
$113.89M
Interest Coverage Ratio
-2256.36x
TTM Avg
-3066.25x
3Y Avg
-1503.59x
5Y Avg
-1146.75x
Market Cap
$114.06M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.57M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.94M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.69M
Interest Coverage Ratio
-280.53x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.51M
Interest Coverage Ratio
-415.73x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.17M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.41M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $113.89M | -2256.36x | -3066.25x | -1503.59x | -1146.75x |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.57M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.94M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | -280.53x | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.51M | -415.73x | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.17M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.41M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.31M | N/A | N/A | N/A | N/A |
Interest Coverage
-2256.4x
Debt/Equity
2.28
Current Ratio
1.33
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -3200.25x |
| 2026-03-31 | -2019.00x |
| 2025-12-31 | -2335.17x |
| 2025-09-30 | -5879.50x |
| 2025-06-30 | -1897.33x |
| 2025-03-31 | -1387.44x |
| 2024-12-31 | -1767.86x |
| 2024-09-30 | -11694.00x |
| 2024-06-30 | -1865.33x |
| 2024-03-31 | -899.33x |
| 2023-12-31 | -1041.18x |
| 2023-09-30 | -74.68x |
| 2023-06-30 | -51.95x |
| 2023-03-31 | -433.85x |
| 2021-12-31 | -172.43x |
| 2021-09-30 | -14.56x |
| 2021-06-30 | -40.93x |
